Мигрень в клинической практике невролога: тернистый путь к рациональной терапии пациентов
- Авторы: Екушева Е.В.1, Филатова Е.Г.1
-
Учреждения:
- ФГБОУ ДПО ИПК
- Выпуск: Том 20, № 2 (2018)
- Страницы: 128-135
- Раздел: Статьи
- URL: https://bakhtiniada.ru/2075-1753/article/view/95115
- DOI: https://doi.org/10.26442/2075-1753_2018.2.128-135
- ID: 95115
Цитировать
Полный текст
Аннотация
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Евгения Викторовна Екушева
ФГБОУ ДПО ИПК
Email: ekushevaev@mail.ru
д-р мед. наук, проф. каф. нервных болезней 125371, Russian Federation, Moscow, Volokolamskoe sh., d. 91
Елена Глебовна Филатова
ФГБОУ ДПО ИПКд-р мед. наук, проф. каф. нервных болезней 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
Список литературы
- Steiner T.J, Birbeck G.L, Jensen R.H et al. Headache disorders are third cause of disability worldwide. J Headache Pain 2015; 16: 58. doi: 10.1186/s10194-015-0544-2
- Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545-602. doi: 10.1016/S0140-6736(16)31678-6
- Tietjen G.E, Collins S.A. Hypercoagulability and migraine. Headache 2018; 58 (1): 173-83. http://dx.doi.org/10.1111/head.13044
- Ayzenberg I, Katsarava Z, Sborowski A et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia 2012; 32 (5): 373-81. doi: 10.1177/0333102412438977
- Bakar N.A, Tanprawate S, Lambru G et al. Quality of life in primary headache disorders: A review. Cephalalgia 2016; 36 (1): 67-91. DOI: 0.1177/0333102415580099
- Sheikh H.U, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a systematic review. Headache 2017. doi: 10.1111/head.13229
- Buse D.C, Reed M.L, Fanning K.M et al. Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2017; 57: 31-44. doi: 10.1111/head.12962
- Peng K-P, Chen Y-T, Fuh J-L et al. Migraine and incidence of ischemic stroke: A nationwide population-based study. Cephalalgia 2017; 37 (4): 327-35. http://dx.doi.org/10.1177/0333102416642602
- Sacco S, Ricci S, Carolei A. Migraine and vascular diseases: a review of the evidence and potential implications for management. Cephalalgia 2012; 32: 785-95. doi: 10.1177/0333102412451361
- Wenzel R, Dortch M, Cady R. Migraine headache misconceptions: Barriers to effective car. Pharmacotherapy 2004; 24: 638-48. doi: 10.1592/phco.24.6.638.34751
- Lucas C, Chaffaut C, Artaz M.A, Lanteri-Minet M. FRAMIG 2000: Medical and therapeutic management of migraine in France. Cephalalgia 2005; 25: 267-79. doi: 10.1111/j.1468-2982.2004.00851.x
- Latinovic R, Gulliford M, Ridsdale L. Headache and migraine in primary care: consultation, prescription, and referral rates in a large population. J Neurol Neurosurg Psychiatry 2006; 77: 385-7. doi: 10.1136/jnnp.2005.073221
- Minen M.T, Loder E, Tishler L, Silbersweig D. Migraine diagnosis and treatment: A knowledge and needs assessment among primary care providers. Cephalalgia 2016; 36 (4): 358-70. http://dx.DOI.org/10.1177/0333102415593086
- Екушева Е.В. Оптимальные подходы к купированию приступа мигрени: прошлое, настоящее и будущее. РМЖ. 2012; 10: 522-8.
- Екушева Е.В., Филатова Е.Г. Головная боль, вызванная сексуальной активностью. Журн. неврологии и психиатрии им. Корсакова. 2003; 103 (10): 21-5.
- Cho S-J, Chu M.K. Risk factors of chronic daily headache or chronic migraine. Curr Pain Headache Rep 2015; 19: 465. doi: 10.1007/s11916-014-0465-9
- Екушева Е.В., Осипова В.В., Артеменко А.Р. Диагностика рефрактерных форм хронической первичной головной боли. Журн. неврологии и психиатрии им. Корсакова. 2017; 117 (1-2): 48-53. doi: 10.17116/jnevro20171171248-53
- Rizzoli P.B. Acute and preventive treatment of migraine. Continuum (Minneap Minn) 2012; 18 (4): 764-82. doi: 10.1212/01.CON.0000418641.45522.3b
- Diamond S, Bigal M.E, Silberstein S. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from American Migraine Prevalence and Preventive study. Headache 2007; 47: 355-63. doi: 10.1111/j.1526-4610.2006.00631.x
- Lucas C, Auray J.P, Gaudin A.F et al. Use and misuse of triptans in France: Data fron the GRIM 2000 population survey. Cephalalgia 2004; 24: 197-205. doi: 10.1111/j.1468-2982.2003.00651.x
- MacGregor E.A, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global migraine and zolmitriptan evaluation survey MAZE. Headache 2003; 43: 19-26. PMID: 12864754
- Ifergane G, Wirguin I, Shvartzman P. Triptans - Why once? Headache 2006; 46: 1261-3. http://dx.DOI.org/10.1111/j.1526-4610.2006.00435.x
- Ferrari M.D, Roon K.I, Lipton R.B, Goadsby P.J. Oral triptans (serotonin 5HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668-75. doi: 10.1016/S0140-6736(01)06711-3
- Gallagner R.M, Dennish G, Spierings E.L.H, Chitra R. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headaсhe 2000; 40: 119-28. PMID: 10759911
- Bird S, Derry S, Moore R.A. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev. 2014; 5: CD008616. doi: 10.1002/14651858.CD008616.pub2
- Spierings E.L, Brandes J.L, Kudrow D.B et al. Randomized, double-blind, placebo controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine. Cephalalgia 2018; 38 (2): 215-24. doi: 10.1177/0333102417737765
- Loder E, Silberstein S.D, Abu-Shakra S et al. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallelgroup, double-blind, placebo-controlled study. Headache 2004; 44: 120-30. PMID: 14756849
- The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33 (9): 629-808. doi: 10.1177/0333102413485658
- Ferrari M.D. Should we advise patients to treat migraine attacks early? Cephalalgia 2004; 24: 915-7. doi: 10.1111/j.1468-2982.2004.00834.x
- Dodick D.W. Triptan nonresponder studies: implications for clinical practice. Headache 2005; 45: 156-62. doi: 10.1111/j.1526-4610.2005.05031.x
- Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneus allodynia. Ann Neurol 2004; 55: 19-26. doi: 10.1002/ana.10786
- Schoenen J, Sawyer J. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT 1B/1D agonist: an overview of efficacy. Cephalalgia 1997; 17: 28-40. doi: 10.1177/0333102497017S1805
- Mauskop A, Farkkila M, Hering-Hanit R et al. Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache. Cur Med Res Opin 1999; 15 (4): 282-9. doi: 10.1185/03007999909116498
- Allais G, Tullo V, Benedetto C et al. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurol Sci 2011; 32 (1): S99-104. doi: 10.1007/s10072-011-0547-y
- Shapero G, Dowson A, Lacoste J-P, Almqvist P. Improved migraine management in primary care: results of a patient treatment experience study using zolmitriptan orally disintegrating tablet. Int J Clin Pract 2006; 60 (12): 1530-5. doi: 10.1111/j.1742-1241.2006.01208
Дополнительные файлы
